

**DAFTAR PUSTAKA**

- AIRE Study Investigators, 1993. Effect of Ramipril on Mortality and Morbidity of Survivors of Acute Myocardial Infarction with Clinical Evidence of Heart Failure. **Lancet**: 342(8875): pp-821-28.
- Bayes-Genis, A. *et al.*, 2014. Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification. **Journal of the American College of Cardiology**: 63(2): pp-158-66.
- Bender, N., Rangoonwala, B., Rosenthal, J. & Vasmant, D., 1990. Physicochemical and Enzyme Binding Kinetic Properties of a New Angiotensin-Converting Enzyme Inhibitor Ramipril and Their Clinical Implications. **Clinical Physiology and Biochemistry**: 8(1): pp-44-52.
- Benowitz, N.L., 2015. Antihypertensive Agents. In B.G. Katzung & A.J. Trevor, eds. **Basic & Clinical Pharmacology**. 13th ed. California: McGraw-Hill Education: pp-169-90.
- Bhandari, B. & Masood, W., 2019. **National Center for Biotechnology Information - Ischemic Cardiomyopathy**. [Online] Available at: <https://www.ncbi.nlm.nih.gov/books/NBK537301/> [Accessed 2019].
- Boer, R.A. *et al.*, 2014. Galectin-3: A Modifiable Risk Factor in Heart Failure. **Cardiovascular Drugs and Therapy**: 28: pp-237-46.
- Chen, K. *et al.*, 2013. Predictive Value of Plasma Galectin-3 in Patients with Chronic Heart Failure. **European Review for Medical and Pharmacological Sciences**: 17: pp-1005-11.
- Chiao, Y.A. & Rabinovitch, P.S., 2015. The Aging Heart. **Cold Spring Harbor Perspective in Medicine**: 5(9): pp-1-15.

- Chow, S.L. *et al.*, 2017. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure - A Scientific Statement From the American Heart Association. **Circulation**: 135: pp-1054-91.
- Dong, R. *et al.*, 2018. Galectin-3 as A Novel Biomarker for Disease Diagnosis and A Target for Therapy (Review). **International Journal of Molecular Medicine**: 41: pp-599-614.
- Dzau, V.J. *et al.*, 2002. Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report. **Cardiovascular Drugs and Therapy**: 16: pp-149-60.
- Edelmann, F. *et al.*, 2015. Galectin-3 in Patients with Heart Failure with Preserved Ejection Fraction: Results from the Aldo-DHF Trial. **European Journal of Heart Failure**: 17: pp-214-23.
- Eisenberg, E., Di Palo, K.E. & Pina, I.L., 2018. Sex Differences in Heart Failure. **Clinical Cardiology**: 41: pp-211-16.
- Farhad, M., Rolig, A.S. & Redmond, W.L., 2018. The role of Galectin-3 in Modulating Tumor Growth and Immunosuppression Within the Tumor Microenvironment. **Oncoimmunology**: 7(6): pp-1-8.
- Frohlich, H. *et al.*, 2018. Comparative Effectiveness of Enalapril, Lisinopril, and Ramipril in the Treatment of Patients with Chronic Heart Failure: A Propensity Score-Matched Cohort Study. **European Heart Journal - Cardiovascular Pharmacotherapy**: 4: pp-82-92.
- Gaggin, H.K. & Januzzi, J.L., 2013. Biomarkers and Diagnostics in Heart Failure. **Biochimica et Biophysica Acta**: 1432: pp-2442-50.
- Gerstein, H.C., 2000. Cardiovascular and Metabolic Benefits of ACE Inhibition. **Diabetes Care**: 23(7): pp-882-83.

- Grandin, E.W. *et al.*, 2012. Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22. **Clinical Chemistry**: 58(1): pp-267-73.
- Gruson, D., Ahn, S., Rousseau, M. & Hermans, M., 2014. Serum Galectin-3 Is Elevated and Related to Cardiac Biomarkers in Types 2 Diabetes. **Journal of Cardiac Failure**: 20(8): pp-102.
- Gullestad, L. *et al.*, 2012. Galectin-3 Predicts Response to Statin Therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). **European Heart Journal**: 33: pp-2290-96.
- Hasenfuss, G. & Mann, D.L., 2019. Pathophysiology of Heart Failure. In D.P. Zipes *et al.*, eds. **Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine**. 11th ed. Philadelphia: Elsevier Inc: pp-442-61.
- Ho, J.E. *et al.*, 2012. Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. **Journal of the American College of Cardiology**: 60(14): pp-1249-56.
- Hrynyshyn, N. *et al.*, 2013. Galectin-3: A New Biomarker for The Diagnosis, Analysis and Prognosis of Acute and Chronic Heart Failure. **Archives of Cardiovascular Disease**: 106: pp-541-46.
- Kang, Q. *et al.*, 2018. Galectin-3 in Patients with Coronary Heart Disease and Atrial Fibrillation. **Clinica Chimica Acta**: 478: pp-166-70.
- Karayannidis, G. *et al.*, 2013. The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers. **Current Heart Failure Reports**: 10: pp-441-49.

- Kaur, T., Sodhi, A., Singh, J. & Arora, S., 2015. Evaluation of Galectin-3 Genetic Variants and its Serum Levels in Rheumatoid Arthritis in North India. **International Journal of Human Genetics**: 15(3): pp-131-38.
- Kementerian Kesehatan RI, 2013. **Riset Kesehatan Dasar 2013**. Jakarta: Badan Penelitian dan Pengembangan Kesehatan: pp-90-94.
- Kementerian Kesehatan RI, 2018. **Laporan Nasional Riskesdas 2018**. Jakarta: Badan Penelitian dan Pengembangan Kesehatan: pp-146-153.
- Kessler, E.L., Rivaud, M.R., Vos, M.A. & Veen, T.A.B., 2019. Sex-specific Influence on Cardiac Structural Remodeling and Therapy in Cardiovascular Disease. **Biology of Sex Differences**: 10(7): pp-1-11.
- Khan, M.S. *et al.*, 2017. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. **Circulation Heart Failure**: 10: pp-1-8.
- Kurmani, S. & Squire, I., 2017. Acute Heart Failure: Definition, Classification and Epidemiology. **Current Heart Failure Reports**: 14: pp-385-92.
- Lok, D.J.A. *et al.*, 2010. Prognostic Value of Galectin-3, A Novel Marker of Fibrosis, in Patients with Chronic Heart Failure: Data from the DEAL-HF Study. **Clinical Research in Cardiology**: 99(5): pp-323-28.
- Mann, D.L. & Chakinala, M., 2015. Heart Failure: Pathophysiology and Diagnosis. In D.L. Kasper *et al.*, eds. **Harrison's Principles of Internal Medicine**. 19th ed. New York: McGraw-Hill Education: pp-1500-06.
- Meijers, W.C. & Boer, R.A., 2012. Galectin-3 Mediated Cardiovascular Fibrogenesis: An Important Cause of Heart Failure and Cardiovascular Mortality. In A. Klyosov & e. al., eds. **Galectins and Disease Implications for Targeted Therapeutics**. Washington: American Chemical Society: pp-397-407.

- Miller, W.L. & Jaffe, A.S., 2016. Biomarkers in Heart Failure: The Importance of Inconvenient Details. **ESC Heart Failure**: 3: pp-3-10.
- Newby, D.E., Grubb, N.R. & Bradbury, A., 2014. Cardiovascular Disease. In B.R. Walker, N.R. Colledge, S.H. Ralston & I.D. Penman, eds. **Davidson's Principles & Practice of Medicine**. 22nd ed. Edinburgh: Elsevier: pp-525-641.
- Nishiyama, J. *et al.*, 2000. Up-Regulation of Galectin-3 in Acute Renal Failure of the Rat. **American Journal of Pathology**: 157(3): pp-815-23.
- Ofstad, A.P. *et al.*, 2018. The Heart Failure Burden of Type 2 Diabetes Mellitus—A Review of Pathophysiology and Interventions. **Heart Failure Reviews**: 23: pp-303-23.
- Ohkura, T. *et al.*, 2014. Low Serum Galectin-3 Concentrations are Associated with Insulin Resistance in Patients with Type 2 Diabetes Mellitus. **Diabetology & Metabolic Syndrome**: 6(106): pp-1-7.
- Opie, L.H. & Pfeffer, M.A., 2013. Inhibitors of the Renin-Angiotensin-Aldosterone System. In L.H. Opie & B.J. Gersh, eds. **Drugs for the Heart**. 8th ed. Philadelphia: Elsevier: pp-119-223.
- Packer, M. *et al.*, 1999. Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure. **Circulation**: 100: pp-2312-18.
- Paneni, F. *et al.*, 2017. The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels. **Journal of the American College of Cardiology**: 69(15): pp-1952-67.
- PERKI, 2015. **Pedoman Tatalaksana Gagal Jantung**. 1st ed. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia: pp-1-48.

- Pfeffer, M.A., 1993. The Survival and Ventricular Enlargement (SAVE) Study: Rationale and Perspective. **Herz**: 1: pp-430-35.
- Pilote, L. *et al.*, 2008. Effect of Different Angiotensin-Converting-Enzyme Inhibitors on Mortality Among Elderly Patients with Congestive Heart Failure. **Canadian Medical Association Journal**: 178(10): pp-1303-11.
- Ponikowski, P. *et al.*, 2016. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. **European Heart Journal**: 37(27): pp-2129-200.
- Prabhu, M. *et al.*, 2005. Therapeutic Dimensions of ACE inhibitors- A Review of Literature and Clinical Trials. **Kathmandu University Medical Journal**: 3(11): pp-296-304.
- Queseda, O. & Klein, L., 2017. Heart Failure with Reduced Ejection Fraction. In M.H. Crawford, ed. **Current Diagnosis & Treatment Cardiology**. 5th ed. New York: McGraw-Hill Education: pp-517-42.
- Roohbakhsh, Y. *et al.*, 2018. Supportive Data for Galectin-3 as a Prognostic Factor in Coronary Artery Disease. **Journal of Cardio-Thoracic Medicine**: 6(4): pp-368-73.
- Savic-Radojevic, A. *et al.*, 2017. Novel Biomarkers of Heart Failure. **Advances in Clinical Chemistry**: 79: pp-93-152.
- Shah, A.D. & Arora, R.R., 2005. Tissue Angiotensin-Converting Enzyme Inhibitors: Are They More Effective than Serum Angiotensin-Converting Enzyme Inhibitors? **Clinical Cardiology**: 28: pp-551-55.
- Shah, R.V. *et al.*, 2010. Galectin-3, Cardiac Structure and Function, and Long-term Mortality in Patients with Acutely Decompensated Heart Failure. **European Journal of Heart Failure**: 12: pp-826-32.

- Singh, H. & Marrs, J.C., 2018. Heart Failure. In C.S. Zeind & M.G. Carvalho, eds. **Applied Therapeutics The Clinical Use of Drugs**. 11th ed. Philadelphia: Wolters Kluwer: pp-261-305.
- Song, L. *et al.*, 2014. Galectin-3 in Cancer. **Clinica Chimica Acta**: 431: pp-185-91.
- Straka, R.J., 2000. **Comparison of Approved ACE Inhibitors**. Minneapolis: Blessing International: pp-1-2.
- Sun, W.P. *et al.*, 2016. Comparison of the Efficacy and Safety of Different ACE Inhibitors in Patients With Chronic Heart Failure. **Medicine**: 95(6): pp-1-8.
- Suthahar, N., Meijers, W.C., Sillje, H.H.W. & Ho, J.E., 2018. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. **Theranostics**: 8(3): pp-593-609.
- Taal, M.W. & Brenner, B.M., 2000. Renoprotective Benefits of RAS Inhibition: From ACEI to Angiotensin II Antagonists. **Kidney International**: 57: pp-1803-17.
- UpToDate, 2019. **Drug Information**. [Online] Available at: [www.uptodate.com](http://www.uptodate.com) [Accessed March 2019].
- Vark, L.C. *et al.*, 2017. Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure. **Journal of the American Heart Association**: 6(12): pp-1-11.
- Velde, A.R. *et al.*, 2013. Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure. **Circulation Heart Failure**: 6: pp-219-26.
- Widiawanto, N., 2015. **Korelasi Antara Kadar Galektin-3 Serum dengan Parameter Ekhokardiografi Fungsi Diastolik Ventrikel Kiri (Rasio E/e') pada Pasien Gagal Jantung dengan Fraksi Ejeksi Normal**. Surabaya: Universitas Airlangga: pp-1-41.
- Wijk, S.S. *et al.*, 2016. Interaction of Galectin-3 Concentrations with the Treatment Effects of B-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A

Derivation-Validation Study from TIME-CHF and GISSI-HF. **Clinical Chemistry**: 62(4): pp-605-16.

World Health Organization, 1991. **Sample Size Determination in Health Studies A Practical Manual**. Geneva: National University of Singapore: pp-1-80.

World Health Organization, 2017. **Cardiovascular Diseases (CVDs)**. [Online] Available at: [http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)) [Accessed August 2018].

Yancy, C.W. *et al.*, 2017. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society America. **Circulation**: 70(6): pp-777-803.

Yancy, C.W. *et al.*, 2013. 2013 ACCF/AHA Guideline for the Management of Heart Failure. **Journal of the American College of Cardiology**: 62(13): pp-147-239.

Zhang, T., Sahao, B. & Liu, G.A., 2017. Research on Clinical Value of Galectin-3 in Evaluating the Prognosis of Acute Heart Failure. **European Review for Medical and Pharmacological Sciences**: 21: pp-4406-10.